Literature DB >> 10388429

Primary alveolar cleft bone grafting in unilateral cleft lip and palate: craniofacial form at age 8.

R R Hathaway1, B L Eppley, C L Nelson, A M Sadove.   

Abstract

Counterpart analysis can be advantageous for the clinician interested in the underlying determinants of the craniofacial form for any given person. This analysis was performed for a group of patients who underwent primary alveolar cleft bone grafting (N = 18) and a group of patients who did not undergo grafting (N = 19) who were 8 years of age (+/- 6 months). The primary grafting group more frequently noted maxillary retrusion, but of a nonsignificant magnitude. Also, the primary grafting group had greater mean magnitudes of mandibular opening as a compensatory adjustment in some patients, but this could not be generalized to all patients who had underdone primary grafting. The mean magnitude of craniofacial vertical shortening was also greater for some patients who had undergone primary grafting, but it, too, did not exhibit a generalized pattern for all patients who had undergone primary alveolar cleft bone grafting procedures. This study emphasizes the great diversity of craniofacial skeletal adjustments made within each group of patients with unilateral cleft lip and palate and cautions the clinician against generalizations concerning a particular treatment protocol.

Entities:  

Mesh:

Year:  1999        PMID: 10388429     DOI: 10.1097/00001665-199901000-00013

Source DB:  PubMed          Journal:  J Craniofac Surg        ISSN: 1049-2275            Impact factor:   1.046


  2 in total

1.  Initial growth pattern of children with cleft before alveolar bone graft stage according to cleft type.

Authors:  Yu-Jin Seo; Ji-Wan Park; Young Ho Kim; Seung-Hak Baek
Journal:  Angle Orthod       Date:  2011-07-15       Impact factor: 2.079

2.  Low intensity pulsed ultrasound therapy: A potential adjuvant treatment for osteonecrosis of alveolar bone grafting.

Authors:  Qi Chen; Bing Shi; Qian Zheng
Journal:  J Res Med Sci       Date:  2013-03       Impact factor: 1.852

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.